Oh Seyeon, Son Myeongjoo, Choi Junwon, Lee Sojung, Byun Kyunghee
Functional Cellular Networks Laboratory, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Republic of Korea.
Functional Cellular Networks Laboratory, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Republic of Korea; Department of Anatomy and Cell Biology, Gachon University Graduate School of Medicine, Incheon 21999, Republic of Korea.
Biochem Biophys Res Commun. 2018 Jan 1;495(1):807-813. doi: 10.1016/j.bbrc.2017.11.035. Epub 2017 Nov 7.
The main causes of Alzheimer's disease (AD) have not determined and effective treatment has not been developed yet, even though extensive researches and several clinical trials have been conducted.. Fortunately, stem cell transplantation is emerging as a potential therapeutic candidate for AD, but the success of stem cell based therapy depends on the survival of transplanted cells. Here, we generated sRAGE secreting mesenchymal stem cells (sRAGE-MSCs) and then injected these MSCs or control MSCs with amyloid beta 1-42 (Aβ) into the entorhinal cortices of male Sprague Dawley rats. The survival of transplanted cell, the number of T lymphocytes and microglia, expression of RAGE and its ligands and neuronal cell death were determined, 4 weeks after sRAGE-MSC transplantation. Transplanted sRAGE-MSCs survived longer than control MSCs and sRAGE-MSCs showed reduced level of CD4 and CD3d positive T lymphocyte. Furthermore, the number of M1 microglia in MSCs was more than that of sRAGE-MSCs as well. On the other hand, the number of M2 microglia in sRAGE-MSCs was increased compared with that of MSCs. In addition, sRAGE-MSCs decreased RAGE and RAGE ligand expressions and their interactions more effectively than those of MSCs. Finally, sRAGE-MSC transplantation protected from apoptosis and prevented decreasing numbers of neuron in Aβ treated rat brains. These observations suggest continuous sRAGE secretion from sRAGE-MSCs might appreciably improve the effectiveness of cell therapy in Aβ injected rat brains.
尽管已经进行了广泛的研究和多项临床试验,但阿尔茨海默病(AD)的主要病因尚未确定,也尚未开发出有效的治疗方法。幸运的是,干细胞移植正在成为AD的一种潜在治疗手段,但基于干细胞的治疗成功与否取决于移植细胞的存活。在此,我们生成了分泌可溶性晚期糖基化终末产物受体(sRAGE)的间充质干细胞(sRAGE-MSCs),然后将这些MSC或对照MSC与β淀粉样蛋白1-42(Aβ)注射到雄性Sprague Dawley大鼠的内嗅皮质中。在sRAGE-MSC移植4周后,测定移植细胞的存活情况、T淋巴细胞和小胶质细胞的数量、RAGE及其配体的表达以及神经元细胞死亡情况。移植的sRAGE-MSCs比对照MSC存活时间更长,并且sRAGE-MSCs显示CD4和CD3d阳性T淋巴细胞水平降低。此外,MSC中的M1小胶质细胞数量也多于sRAGE-MSCs。另一方面,与MSC相比,sRAGE-MSCs中的M2小胶质细胞数量增加。此外,sRAGE-MSCs比MSC更有效地降低RAGE和RAGE配体的表达及其相互作用。最后,sRAGE-MSC移植可保护Aβ处理的大鼠大脑中的神经元免于凋亡并防止神经元数量减少。这些观察结果表明,sRAGE-MSCs持续分泌sRAGE可能会显著提高Aβ注射大鼠大脑中细胞治疗的效果。
Biochem Biophys Res Commun. 2018-1-1
Mol Cell Biochem. 2019-5-11
Int J Clin Exp Pathol. 2015-10-1
Curr Drug Targets CNS Neurol Disord. 2005-6
Neuromolecular Med. 2012-3-14
Biomedicines. 2023-1-3
Curr Neuropharmacol. 2022